AngioDynamics Releases Two-Year Data from PRESERVE Trial for NanoKnife IRE System
AngioDynamics announced two-year results from the PRESERVE trial, showing durable oncologic control and a sustained safety profile for the NanoKnife System in treating intermediate-risk prostate cancer. The data highlights the potential of the NanoKnife IRE System in focal ablation procedures.
LATHAM, N.Y.–(BUSINESS WIRE)–AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, today announced two-year results from the PRESERVE pivotal trial (NCT04972097) demonstrating durable oncologic control and a sustained safety profile for the NanoKnife System in the focal ablation of intermediate-risk prostate cancer. The data will be discus